Thus, Nrf2 activators could be effective in breaking down α-syn aggregates and hampering NF-κB-associated neuroinflammation elucidated in PD via maintaining cellular redox homeostasis (Chakkittukandiyil et al. 2022; de Siqueira et al. 2023). This evidence concerns the gene NFE2L2 and Parkinson disease.